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Indrani Sen, MS, Dheepak Selvaraj, MS, Prabhu Premkumar, MS, and Sunil Agarwal, MS, Vellore,
Tamilnadu, India
A 24-year-old man presented with impending ulceration of a large thigh swelling which appeared after minor trauma.
Imaging revealed a large well-encapsulated lesion with no vascularity. He was diagnosed to have a pseudotumor and
underwent successful excision of the mass under blood and cryoprecipitate cover. The unusual presentation was suspected
to be secondary to a transient drug-induced factor XIII deﬁciency because the result of the ﬁnal coagulation study was
normal. (J Vasc Surg Cases 2015;1:187-90.)We report the management of a pseudotumor occur-
ring due to a transient factor XIII deﬁciency. A pseudotu-
mor is a chronic progressive swelling due to recurrent
hemorrhage into soft tissue. Although benign, it mimics
a sarcoma, hence the name. A high degree of suspicion is
necessary to diagnose these slow-growing masses. Opera-
tive management requires a multidisciplinary team with
experience in the management of rare bleeding disorders.
The patient consented to the publication of this report.
CASE REPORT
A 24-year-old man presented with a gradually increasing
swelling of the right thigh for 1 year, with skin ulceration for
1 month. He sustained minor trauma (fall onto his right leg)
1 year previously. He received empirical antituberculous treatment
(ATT) elsewhere for a year. He did not have family history of
bleeding disorders.
On examination there was a 24-cm  16-cm  12-cm right
upper thigh swelling with skin ulceration (Fig 1). There was no
abnormal pulsation or bruit. Magnetic resonance imaging revealed
a complex heterogeneous well-encapsulated lesion in the anterolat-
eral aspect of the right thigh (Fig 2). Comparison with earlier im-
aging revealed an increase in the size. Adjacent bones were normal,
and there were no air pockets. Duplex screening ruled out a pseu-
doaneurysm. Differentials considered were schwannoma or neuro-
ﬁbroma with necrosis, soft tissue sarcoma, or pseudotumor.
Coagulation proﬁle testing revealed a hemoglobin value, total
counts, and platelet counts within normal reference ranges. There
was a prolonged prothrombin time, activated partial thrombo-
plastin time (aPTT) and thrombin time, which corrected with con-
trol plasma. The prolonged aPTT did not correct with aged serum
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platelet aggregometry results were within normal reference ranges.
The mass was diagnosed to be a pseudotumor. Management
involved a multidisciplinary team that included vascular and ortho-
pedic surgeons, hematology and transfusion medicine physicians,
and interventional radiology.
After arterial embolization of branches from the internal iliac
and profunda (Fig 3), the pseudotumor was excised with the pa-
tient under general anesthesia. The mass was approached by an
anterolateral thigh incision from the anterior-superior iliac spine
to the patella. There was no deﬁnite intermuscular plane, and an
incision was made into the capsule. Two liters of altered blood
and clots were suctioned out. After this decompression, the pseu-
dotumor capsule was excised with ligation of all adherent vessels
circumferentially. The surgical wound was packed, and hemostasis
of the muscle bed was achieved by surgical ligation and cautery
along with the use of ﬁbrin glue and topical hemostats. The total
operative blood loss was 3.51 L. Perioperative concentrations of
hemoglobin, platelets, ﬁbrinogen, prothrombin time, aPTT, and
thromboelastography were used to guide replacement therapy,
and 5 units of packed cells, 4 units of platelet-rich concentrates,
15 units of cryoprecipitate, and 4 units of fresh frozen plasma
were administered. The excess redundant skin was excised and
the wound closed in layers over a closed nonsuction drain.
Postoperatively, the patient did not require continued support
with blood or blood products. The drain contained serosanguine-
ous ﬂuid for the ﬁrst 2 days, after which contents were serous. It
was removed in a week, after the volume reduced to <10 mL.
The pathology report was consistent with an organized hematoma.
DISCUSSION
Hemophilic pseudotumor is an encapsulated hema-
toma with calciﬁcation and ossiﬁcation caused by recurrent
bleeding in patients with coagulation disorders. It was ﬁrst
described by Valderrama and Matthews.1 Soft tissue
chronic expanding hematomas are a similar condition
where there is an increasing hematoma present
>1 month after the inciting trauma. However, these lack
a deﬁnitive etiology, and patients have no underlying coag-
ulation abnormality.2
We searched all available MEDLINE, Science Direct,
and Ovid records using “hemophilia, hemophiliac, pseudo-
tumor, cyst, factor XIII, acquired, chronic hematoma, and
surgery” as search words. This is the ﬁrst report of187
Fig 1. Clinical presentation: swelling in the right thigh with an area of ulceration (red arrow).
Fig 2. Preoperative magnetic resonance imaging shows a
pseudotumor of the right thigh.
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with an acquired transient coagulation disorder.3-17
Pseudotumors occur in 1% to 2 % of patients with hemo-
philia, platelet disorders, or other factor deﬁciencies.2 With
early detection of muscle bleeding in patients with hemo-
philia, occurrence of life-threatening pseudotumors are
rare but may still be seen where factor and blood product
support is not easily available. Clinically, they present with
a slow-growing localizedmass present for many years. There
are two subtypes. Proximal pseudotumors occur due to sub-
periosteal, intraosseous, or intramuscular bleeding in the
adult femur or pelvic areas prone to repetitive trauma. These
do not respond to conservative treatment. Distal pseudotu-
mors occur in epiphyseal growth plates in children and may
resolve with replacement therapy and immobilization.2
Pressure effects on adjacent soft tissue may lead to skin ne-
crosis, bleeding, pain, neurologic deﬁcits, contractures,
and impaired mobility. Secondary infection or ruptures
into an adjacent viscus are rare complications.
Imaging is the mainstay of diagnosis. A pseudotumor
in soft tissue can be classiﬁed as intramuscular or extramus-
cular (interfascial, subcutaneous, osseous, and subperios-
teal). Ultrasound imaging helps in the diagnosis,
differentiation from a pseudoaneurysm, and follow-up of
a smaller lesion. Computed tomography reveals mass le-
sions of variable density, calciﬁcation, focal bone formation,
erosion, periosteal reaction, or medullary destruction. The
presence of gas indicates secondary infection. Enhanced
computed tomography deﬁnes the outlines and wall thick-
ness of the peripheral enhancing capsule, relation to the
vascular structures, and rules out a pseudoaneurysm.
Magnetic resonance imaging can distinguish between
acute (1-6 days) and chronic hemorrhage and differentiate
the mass from soft tissue sarcomas, parasitic cysts, or other
tumors. Management is guided by the site, size, rate of
growth, or presence of pressure effects. The risk of blood
loss and need for blood/product support makes
Fig 3. Embolization for pseudotumor of the right thigh. Branches from the internal iliac (top left) and profunda
(top right). Arterial embolization with reduction in capsule vadcularity (bottom row).
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tissue tumor may rarely necessitate a biopsy.
Conservative measuresdfactor replacement, moni-
toring with radiologic imaging, and drainage or
aspirationdare indicated in small acute lesions, with repeatimaging to guide duration of treatment. Aspiration/
drainage in chronic lesions is usually unsuccessful because
of the presence of organized hematoma, which cannot be
evacuated without operative intervention.1,2 Fibrin glue in-
jection, bone graft, hydroxyapatite ﬁlling, arterial
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and drainage is contraindicated in large lesions due to the
risk of massive hemorrhage, persistent oozing from the
remnant capsule, and infection.1,2 Embolization reduces
the blood supply to the densely adherent capsule in large
tumors, reducing bleeding from the muscle bed.18,19 Sur-
gical excision under blood/product cover is indicated for
larger lesions or when complications occur. Amputation
may be necessary in patients who have a nonfunctional
limb, long-bone fracture, uncontrollable hemorrhage, or
a massive lesion with unacceptable risk from excision.
Pseudotumors occurring in patients with coagulopa-
thies other than hemophilia, such as acquired factor XIII
deﬁciency,3-6 are even rarer. Acquired factor XIII deﬁ-
ciency can occur due to decrease protein synthesis or auto-
antibodies in malignancy, irritable bowel disease,
autoimmune disorders, pulmonary thromboembolism,
stroke, cirrhosis, sepsis, disseminated intravascular coagula-
tion, major surgery, or medications. Medications can cause
acquired XIII deﬁciency. Use of isoniazid, penicillin,
phenytoin, or practolol is associated with this complication,
and patients present with intramuscular/retroperitoneal
bleeding occurring 1 to 8 years after the initiation of medi-
cation. It can be fatal if not treated promptly. Stopping the
causative medication reverses the coagulopathy in weeks to
months. Other medications, such as prednisolone, cyclo-
phosphamide, and rituximab are used for treatment when
indicated.8,9 Operative intervention is necessary in large le-
sions or when complications occur.
CONCLUSIONS
Successful surgical management of pseudotumors
requires a multidisciplinary team with experience in man-
agement of rare bleeding disorders.
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